AsCO Oral Report Overview of Hepatocellular Carcinoma (HCC)

As a result of the COVID-19 outbreak, the 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO2020) will be held in the form of an online meeting on May 29-31, 2020 ESTThe conference will provide more than 250 oral summary presentations and 2,500 poster presentations based on 24 diseases and professionsrecently, asCO annual meeting has published a summary of most of the research online (except LBA)Follow the pace of small editors, open the "cloud annual meeting" model, preemptively browse this year's ASCO annual meeting selected part of the domestic oral reportLast time we shared breast cancer-related content, this time we looked at the relevant content of liver cancerDonafenib and sorafenib as a first-line treatment for advanced hepatocellular carcinoma: an open label, randomized, multicenter PHASE II/III trialProfessor Bi Feng of Huaxi Hospital, Sichuan University, and otherbackground:Solafini is still the standard first-line treatment for advanced hepatocellular carcinoma (HCC)Donatini is a new type of multikinase inhibitor that has shown potential benefits in previous HCC Ib studiesmethod:in this open-label randomized Phase II / Phase III clinical trial (ZGDH3), patients with non-recative or metastatic HCC, Child-Pugh liver function score of 7 and no systemic treatment in the past were selected, randomized (1: 1) twice a day oral donated donated donated donated donated donated donaphany (0.2 g) or solafenni (0.4 g) until the disease progression or disease progressionThe primary endpoint is total lifetime (OS)Efficacy analysis is primarily based on a full analysis set (FAS)results:randomly grouped 668 patients (Donafini (334) and Sorafini (334) in a random group between March 2016 and April 2018, and included in the Intentional Therapy (ITT) group, in which FAS analyzed 659 patients (328 vs 331)Compared to Sorafini, The risk ratio of 12.1 months to 10.3 months, the risk ratio was 0.831, 95% confidence interval 0.699-0.988, p.0363) and ITT (12.0 months vs10.1 months, 0.839, 0.706-0.996, 0.04% of the os) extended significantlyMedian progression survival (3.7 months vs3.6 months, p.2824), objective mitigation rate (4.6% vs2.7%, p.2448) and disease control rate (30.8% vs28.7%, p.5532) were no significant differenceThere were 191 (57.4%) and 224 (67.5%) patients with level 3 or more adverse events (AE) (p s 0.0082), respectively, and AE of particular concern and AE caused by treatment interruption occurred 287 (86.2%) vs 309 (93.1%, p s 0.0049) and 101 (30.3%) vs141 (42.5%, p - 0.0013)A smaller number of patients treated with Donatini reported severe adverse events (55 (16.5%) compared to 67 (20.2%) and p-0.2307Common adverse events in Donatini included skin reactions in the hands and feet (50.5%), increased transaminase in the winterine (40.5%), increased hetocopelaline (39.0%), decreased platelet count (37.8%) and diarrhea (36.6%)conclusion:significantly improved OS compared to Sorafeni and had good safety and toleranceDonovan is expected to be a premium first-line drug for the treatment of advanced HCCApatini as a second-line treatment for advanced hepatocellular carcinoma in China: a randomized, placebo-controlled, double-blind, Phase III studyProfessor Li Qiu of Huaxi Hospital, Sichuan University, and otherbackground: Chinese patients account for more than 50% of global hepatocellular carcinoma (HCC) cases, and have special characteristics in terms of etiology, biological behavior, treatment strategies and prognosis The purpose of this study was to assess the efficacy and safety of apatinib, an inhibitor of the endothelial growth factor receptor 2 targeted in pre-treated patients with advanced HCC method: were selected for at least one system therapy (including sorafeni and osalipriate-based chemotherapy, another first-line therapy in China) and hCC patients with a Grade A or B-7 rating in this clinical trial in 31 regions of China Patients were randomly assigned (2:1), taken by oral 750 mg of apatine or placebo once a day, and stratified by ECOG performance (0 or 1) over a 28-day treatment period, both solafenithein (yes or no), hepatopathic diffusion and/or large vascular immersion (yes or no) The primary endpoint is the total lifetime (OS) results: randomly grouped 393 patients and received at least one dose of the study treatment (261 in the Appaltinib group and 132 in the placebo group) between April 1, 2014 and May 03, 2017 The median OS of appatinib is significantly longer than placebo (8.7 months (8.7 months ( 95% CI 7.5-9.8) vs 6.8 months ( 95% CI 5.7-9.1) ; Compared to the placebo group, the median progression-free survival (PFS) in patients in the Appaltinib group was also extended (4.5 months (95% CI 3.9-4.7) vs 1.9 months (95% CI 1.9-2.0 ;p); The objective remission rate of apatinib was 10.7% (95% CI 7.2-15.1), while the placebo was 1.5% (95% CI 0.2-5.4) Treatment-related adverse events (TRAE) were reported to be 250 (97.3%) in the Appatinib group and 92 (70.8%) in the placebo group The most common level3 to 4 treatment-related adverse events (TRAEs) at levels 3 and 4 are hypertension (Appatinib group 71 (27.6%) PTS VS, hand-foot syndrome (46 (17.9%), placebo group 3 (2.3%)) VS 0), platelet count decrease (34 (13.2%)vs 1 (0.8%), neutrophil count decrease (27 s.10.5% vs vs0) No adverse events were found in 24 (9.3%) patients (9.3%) and 13 (10.0%) who took a placebo conclusion: in patients with advanced liver cancer in China, apatine can significantly extend OS and PFS, and has good tolerance and good safety author: Ren Ran Source:
health